Q&A with Dr. Philip Awadalla.

Pre-diagnosis plasma cell-free DNA is linked to early signatures of prostate and breast cancer risk as far as eight years before clinical detection.

• Why it matters: Early detection is limited because cancer often becomes clinically apparent only after progression, so identifying long-lead biomarkers could improve risk recognition.
• What they did: The work analyzes pre-diagnosis plasma cell-free DNA to detect early signals of prostate and breast cancer risk, extending the observation window up to eight years prior to diagnosis.
• The result: The findings suggest that cell-free DNA profiles can reveal early risk-associated signatures well before clinical detection, enabling earlier identification of individuals at risk.

AI summary of the abstract · may contain errors · not medical advice · read the paper.